Please login to the form below

Not currently logged in
Email:
Password:

Valchlor

This page shows the latest Valchlor news and features for those working in and with pharma, biotech and healthcare.

EU nod for Actelion's skin cancer drug Ledaga

EU nod for Actelion's skin cancer drug Ledaga

The Swiss biotech - which already sells Ledaga (mechlorethamine or chlormethine) under the Valchlor brand in the US - notes that the European Commission cleared the drug as a topical treatment for mycosis ... Actelion acquired Valchlor in 2013 when it

Latest news

  • Actelion partners with PatientsLikeMe on blood cancer research Actelion partners with PatientsLikeMe on blood cancer research

    Mitchell Nagao, Actelion's senior director - medical head of Valchlor and Zavesca, said: “As changes in technology, culture, and treatment affect how patients live with disease, we want measurement to evolve

  • Actelion complete Ceptaris purchase Actelion complete Ceptaris purchase

    light to Valchlor (mechlorethamine hydrochloride) as a treatment for patients with early-stage mycosis fungoides-type cutaneous T-cell lymphoma (CTL). ... Such preparations do not undergo the same rigorous FDA review as Valchlor," he added.

  • Actelion to buy Ceptaris - if FDA backs its cancer treatment Actelion to buy Ceptaris - if FDA backs its cancer treatment

    Acquisition contingent on Valchlor approval in rare lymphoma. Actelion is set to acquire US-based biopharma Ceptaris, but only if US regulators approve Ceptaris' cancer treatment Valchlor. ... Valchlor is also under review in Europe where it is also

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics